• 1
    Iozzo RV (1998) Matrix proteoglycans: from molecular design to cellular function. Annu Rev Biochem 67, 609652.
  • 2
    Schaefer L & Schaefer RM (2010) Proteoglycans: from structural compounds to signaling molecules. Cell Tissue Res 339, 237246.
  • 3
    Syrokou A, Tzanakakis G, Tsegenidis T, Hjerpe A & Karamanos NK (1999) Effects of glycosaminoglycans on proliferation of epithelial and fibroblast human malignant mesothelioma cells: a structure–function relationship. Cell Prolif 32, 8599.
  • 4
    Wight TN (2002) Versican: a versatile extracellular matrix proteoglycan in cell biology. Curr Opin Cell Biol 14, 617623.
  • 5
    Wight TN & Merrilees MJ (2004) Proteoglycans in atherosclerosis and restenosis: key roles for versican. Circ Res 94, 11581167.
  • 6
    Theocharis AD (2008) Versican in health and disease. Connect Tissue Res 49, 230234.
  • 7
    Wu YJ, Lapierre D, Wu J, Yee AJ & Yang BB (2005) The interaction of versican with its binding partners. Cell Res 15, 483494.
  • 8
    Kim S, Takahashi H, Lin WW, Descargues P, Grivennikov S, Kim Y, Luo JL & Karin M (2009) Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature 457, 102106.
  • 9
    Sakko AJ, Ricciardelli C, Mayne K, Tilley WD, LeBaron RG & Horsfall DJ (2001) Versican accumulation in human prostatic fibroblast cultures is enhanced by prostate cancer cell-derived transforming growth factor beta1. Cancer Res 61, 926930.
  • 10
    Ricciardelli C, Brooks JH, Suwiwat S, Sakko AJ, Mayne K, Raymond WA, Seshadri R, LeBaron RG & Horsfall DJ (2002) Regulation of stromal versican expression by breast cancer cells and importance to relapse-free survival in patients with node-negative primary breast cancer. Clin Cancer Res 8, 10541060.
  • 11
    Nikitovic D, Zafiropoulos A, Katonis P, Tsatsakis A, Theocharis AD, Karamanos NK & Tzanakakis GN (2006) Transforming growth factor-beta as a key molecule triggering the expression of versican isoforms v0 and v1, hyaluronan synthase-2 and synthesis of hyaluronan in malignant osteosarcoma cells. IUBMB Life 58, 4753.
  • 12
    Arslan F, Bosserhoff AK, Nickl-Jockschat T, Doerfelt A, Bogdahn U & Hau P (2007) The role of versican isoforms V0/V1 in glioma migration mediated by transforming growth factor-beta2. Br J Cancer 96, 15601568.
  • 13
    Serra M, Miquel L, Domenzain C, Docampo MJ, Fabra A, Wight TN & Bassols A (2005) V3 versican isoform expression alters the phenotype of melanoma cells and their tumorigenic potential. Int J Cancer 114, 879886.
  • 14
    Miquel-Serra L, Serra M, Hernández D, Domenzain C, Docampo MJ, Rabanal RM, de Torres I, Wight TN, Fabra A & Bassols A (2006) V3 versican isoform expression has a dual role in human melanoma tumor growth and metastasis. Lab Invest 86, 889901.
  • 15
    Ricciardelli C, Mayne K, Sykes PJ, Raymond WA, McCaul K, Marshall VR & Horsfall DJ (1998) Elevated levels of versican but not decorin predict disease progression in early stage prostate cancer. Clin Cancer Res 4, 963971.
  • 16
    Pirinen R, Leinonen T, Böhm J, Johansson R, Ropponen K, Kumpulainen E & Kosma VM (2005) Versican in nonsmall cell lung cancer: relation to hyaluronan, clinicopathologic factors, and prognosis. Hum Pathol 36, 4450.
  • 17
    Pukkila M, Kosunen A, Ropponen K, Virtaniemi J, Kellokoski J, Kumpulainen E, Pirinen R, Nuutinen J, Johansson R & Kosma VM (2007) High stromal versican expression predicts unfavourable outcome in oral squamous cell carcinoma. J Clin Pathol 60, 267272.
  • 18
    Labropoulou VT, Theocharis AD, Ravazoula P, Perimenis P, Hjerpe A, Karamanos NK & Kalofonos HP (2006) Versican but not decorin accumulation is related to metastatic potential and neovascularization in testicular germ cell tumors. Histopathology 49, 582593.
  • 19
    Suwiwat S, Ricciardelli C, Tammi R, Tammi M, Auvinen P, Kosma VM, LeBaron RG, Raymond WA, Tilley WD & Horsfall DJ (2004) Expression of extracellular matrix components versican, chondroitin sulfate, tenascin, and hyaluronan, and their association with disease outcome in node negative breast cancer. Clin Cancer Res 10, 24912498.
  • 20
    Kodama J, Hasengaowa, Kusumoto T, Seki N, Matsuo T, Nakamura K, Hongo A & Hiramatsu Y (2007) Versican expression in human cervical cancer. Eur J Cancer 43, 14601466.
  • 21
    Kodama J, Hasengaowa, Kusumoto T, Seki N, Matsuo T, Ojima Y, Nakamura K, Hongo A & Hiramatsu Y (2007) Prognostic significance of stromal versican expression in human endometrial cancer. Ann Oncol 18, 269274.
  • 22
    Mauri P, Scarpa A, Nascimbeni AC, Benazzi L, Parmagnani E, Mafficini A, Della Peruta M, Bassi C, Miyazaki K & Sorio C (2005) Identification of proteins released by pancreatic cancer cells by multidimensional protein identification technology: a strategy for identification of novel cancer markers. FASEB J 19, 11251127.
  • 23
    Cattaruzza S, Schiappacassi M, Kimata K, Colombatti A & Perris R (2004) The globular domains of PGM/versican modulate the proliferation–apoptosis equilibrium and invasive capabilities of tumor cells. FASEB J 18, 779781.
  • 24
    Zheng PS, Wen J, Ang LC, Sheng W, Viloria-Petit A, Wang Y, Wu Y, Kerbel RS & Yang BB (2004) Versican/PG-M G3 domain promotes tumor growth and angiogenesis. FASEB J 18, 754756.
  • 25
    Ricciardelli C, Russell DL, Ween MP, Mayne K, Suwiwat S, Byers S, Marshall VR, Tilley WD & Horsfall DJ (2007) Formation of hyaluronan- and versican-rich pericellular matrix by prostate cancer cells promotes cell motility. J Biol Chem 282, 1081410825.
  • 26
    LaPierre DP, Lee DY, Li SZ, Xie YZ, Zhong L, Sheng W, Deng Z & Yang BB (2007) The ability of versican to simultaneously cause apoptotic resistance and sensitivity. Cancer Res 67, 47424750.
  • 27
    Yee AJ, Akens M, Yang BL, Finkelstein J, Zheng PS, Deng Z & Yang B (2007) The effect of versican G3 domain on local breast cancer invasiveness and bony metastasis. Breast Cancer Res 9, R47.
  • 28
    Touab M, Villena J, Barranco C, Arumi-Uria M & Bassols A (2002) Versican is differentially expressed in human melanoma and may play a role in tumor development. Am J Pathol 160, 549557.
  • 29
    Sakko AJ, Ricciardelli C, Mayne K, Suwiwat S, LeBaron RG, Marshall VR, Tilley WD & Horsfall DJ (2003) Modulation of prostate cancer cell attachment to matrix by versican. Cancer Res 63, 47864791.
  • 30
    Zhang Y, Cao L, Yang BL & Yang BB (1998) The G3 domain of versican enhances cell proliferation via epidermal growth factor-like motifs. J Biol Chem 273, 2134221351.
  • 31
    Yang BL, Zhang Y, Cao L & Yang BB (1999) Cell adhesion and proliferation mediated through the G1 domain of versican. J Cell Biochem 72, 210220.
  • 32
    Wang W, Xu G-L, Jia W-D, Ma J-L, Li J-S, Ge Y-S, Ren W-H, Yu J-H & Liu W-B (2009) Ligation of TLR2 by versican: a link between inflammation and metastasis. Arch Med Res 40, 321323.
  • 33
    Naso MF, Zimmermann DR & Iozzo RV (1994) Characterization of the complete genomic structure of the human versican gene and functional analysis of its promoter. J Biol Chem 269, 3299933008.
  • 34
    Yoon H, Liyanarachi S, Wright FA, Davuluri R, Lockman JC, Chapelle A & Pellegata NS (2002) Gene expression profiling of isogenic cells with different TP53 gene dosage reveals numerous genes that are affected by TP53 dosage and identifies CSPG2 as a direct target of p53. Proc Natl Acad Sci USA 99, 1563215637.
  • 35
    Willert J, Epping M, Pollack JR, Brown PO & Nusse R (2002) A transcriptional response to Wnt protein in human embryonic carcinoma cells. BMC Dev Biol 2, 8. doi: 10.1186/1471-213X-2-8.
  • 36
    Berdiaki A, Zafiropoulos A, Fthenou E, Katonis P, Tsatsakis A, Karamanos NK & Tzanakakis GN (2008) Regulation of hyaluronan and versican deposition by growth factors in fibrosarcoma cell lines. Biochim Biophys Acta 1780, 194202.
  • 37
    Syrokou A, Tzanakakis GN, Hjerpe A & Karamanos NK (1999) Proteoglycans in human malignant mesothelioma. Stimulation of their synthesis induced by epidermal, insulin and platelet-derived growth factors involves receptors with tyrosine kinase activity. Biochimie 81, 733744.
  • 38
    Shimizu-Hirota R, Sasamura H, Mifune M, Nakaya H, Kuroda M, Hayashi M & Saruta T (2001) Regulation of vascular proteoglycan synthesis by angiotensin II type 1 and type 2 receptors. J Am Soc Nephrol 12, 26092615.
  • 39
    Lee DY, Shatseva T, Jeyapalan Z, Du WW, Deng Z & Yang BB (2009) A 3′-untranslated region (3′UTR) induces organ adhesion by regulating miR-199a* functions. PLoS ONE 4, e4527. doi:10.1371/journal.pone.0004527.
  • 40
    Migliore C, Petrelli A, Ghiso E, Corso S, Capparuccia L, Eramo A, Comoglio PM & Giordano S (2008) MicroRNAs impair MET-mediated invasive growth. Cancer Res 68, 1012810136.
  • 41
    Seto AG (2010) The road toward microRNA therapeutics. Int J Biochem Cell Biol 42, 12981305.
  • 42
    Ricciardelli C, Sakko AJ, Ween MP, Russell DL & Horsfall DJ (2009) The biological role and regulation of versican levels in cancer. Cancer Metastasis Rev 28, 233245.
  • 43
    Almholt K, Juncker-Jensen A, Laerum OD, Danø K, Johnsen M, Lund LR & Rømer J (2008) Metastasis is strongly reduced by the matrix metalloproteinase inhibitor Galardin in the MMTV-PymT transgenic breast cancer model. Mol Cancer Ther 7, 27582767.
  • 44
    Vankemmelbeke MN, Jones GC, Fowles C, Ilic MZ, Handley CJ, Day AJ, Knight CG, Mort JS & Buttle DJ (2003) Selective inhibition of ADAMTS-1, -4 and -5 by catechin gallate esters. Eur J Biochem 270, 23942403.
  • 45
    Zeng C, Toole BP, Kinney SD, Kuo JW & Stamenkovic I (1998) Inhibition of tumor growth in vivo by hyaluronan oligomers. Int J Cancer 77, 396401.
  • 46
    Misra S, Toole BP & Ghatak S (2006) Hyaluronan constitutively regulates activation of multiple receptor tyrosine kinases in epithelial and carcinoma cells. J Biol Chem 281, 3493634941.
  • 47
    Skandalis SS, Theocharis AD, Vynios DH, Papageorgakopoulou N, Hjerpe A, Karamanos NK & Theocharis DA (2006) Cartilage aggrecan undergoes significant compositional and structural alterations during laryngeal cancer. Biochim Biophys Acta 1760, 10461055.
  • 48
    Skandalis SS, Theocharis AD, Theocharis DA, Papadas T, Vynios DH & Papageorgakopoulou N (2004) Matrix proteoglycans are markedly affected in advanced laryngeal squamous cell carcinoma. Biochim Biophys Acta 1689, 152161.
  • 49
    Nutt CL, Zerillo CA, Kelly GM & Hockfield S (2001) Brain enriched hyaluronan binding (BEHAB)/brevican increases aggressiveness of CNS-1 gliomas in Lewis rats. Cancer Res 61, 70567059.
  • 50
    Hu B, Kong LL, Matthews RT & Viapiano MS (2008) The proteoglycan brevican binds to fibronectin after proteolytic cleavage and promotes glioma cell motility. J Biol Chem 283, 2484824859.
  • 51
    Viapiano MS, Bi WL, Piepmeier J, Hockfield S & Matthews RT (2005) Novel tumor-specific isoforms of BEHAB/brevican identified in human malignant gliomas. Cancer Res 65, 67266733.
  • 52
    Schaefer L & Iozzo RV (2008) Biological functions of the small leucine-rich proteoglycans: from genetics to signal transduction. J Biol Chem 283, 2130521309.
  • 53
    Iozzo RV & Schaefer L (2010) Proteoglycans in health and disease: novel regulatory signaling mechanisms evoked by the small leucine-rich proteoglycans. FEBS J 277, 38643875.
  • 54
    Iozzo RV, Chakrani F, Perrotti D, McQuillan DJ, Skorski T, Calabretta B & Eichstetter I (1999) Cooperative action of germline mutations in decorin and p53 accelerates lymphoma tumorigenesis. Proc Natl Acad Sci USA 96, 30923097.
  • 55
    Csordas G, Santra M, Reed CC, Eichstetter I, McQuillan DJ, Gross D, Nugent MA, Hajnoczky G & Iozzo RV (2000) Sustained down-regulation of the epidermal growth factor receptor by decorin. A mechanism for controlling tumor growth in vivo. J Biol Chem 275, 3287932887.
  • 56
    Santra M, Mann DM, Mercer EW, Skorski T, Calabretta B & Iozzo RV (1997) Ectopic expression of decorin protein core causes a generalized growth suppression in neoplastic cells of various histogenetic origin and requires endogenous p21, an inhibitor of cyclin-dependent kinases. J Clin Invest 100, 149157.
  • 57
    Santra M, Eichstetter I & Iozzo RV (2000) An anti-oncogenic role for decorin: downregulation of ErbB2 leads to growth suppression and cytodifferentiation of mammary carcinoma cells. J Biol Chem 275, 3515335161.
  • 58
    Gialeli Ch, Kletsas D, Mavroudis D, Kalofonos HP, Tzanakakis GN & Karamanos NK (2009) Targeting epidermal growth factor receptor in solid tumors: critical evaluation of the biological importance of therapeutic monoclonal antibodies. Curr Med Chem 16, 37973804.
  • 59
    Zhu J-X, Goldoni S, Bix G, Owens RA, McQuillan D, Reed CC & Iozzo RV (2005) Decorin evokes protracted internalization and degradation of the EGF receptor via caveolar endocytosis. J Biol Chem 280, 3246832479.
  • 60
    Reed CC, Waterhouse A, Kirby S, Kay P, Owens RA, McQuillan DJ & Iozzo RV (2005) Decorin prevents metastatic spreading of breast cancer. Oncogene 24, 11041110.
  • 61
    Zafiropoulos A, Nikitovic D, Katonis P, Tsatsakis A, Karamanos NK & Tzanakakis GN (2008) Decorin-induced growth inhibition is overcome through protracted expression and activation of epidermal growth factor receptors in osteosarcoma cells. Mol Cancer Res 6, 785794.
  • 62
    Goldoni S, Humphries A, Nyström A, Sattar S, Owens RT, McQuillan DJ, Ireton K & Iozzo RV (2009) Decorin is a novel antagonistic ligand of the Met receptor. J Cell Biol 185, 743754.
  • 63
    Newton TR, Parsons PG, Lincoln DJ, Cummings MC, Wyld DK, Webb PM, Green AC & Boyle GM (2006) Expression profiling correlates with treatment response in women with advanced serous epithelial ovarian cancer. Int J Cancer 119, 875883.
  • 64
    Troup S, Njue C, Kliewer EV, Parisien M, Roskelley C, Chakravarti S, Roughley PJ, Murphy LC & Watson PH (2003) Reduced expression of the small leucine-rich proteoglycans, lumican, and decorin is associated with poor outcome in node-negative invasive breast cancer. Clin Cancer Res 9, 207214.
  • 65
    Matsumine A, Shintani K, Kusuzaki K, Matsubara T, Satonaka H, Wakabayashi T, Iino T & Uchida A (2007) Expression of decorin, a small leucine-rich proteoglycan, as a prognostic factor in soft tissue tumors. J Surg Oncol 96, 411418.
  • 66
    Theocharis AD (2002) Human colon adenocarcinoma is associated with specific post-translational modifications of versican and decorin. Biochim Biophys Acta 1588, 165172.
  • 67
    Nash MA, Deavers MT & Freedman RS (2002) The expression of decorin in human ovarian tumors. Clin Cancer Res 8, 17541760.
  • 68
    Theocharis AD, Vynios DH, Papageorgakopoulou N, Skandalis SS & Theocharis DA (2003) The gastric carcinoma glycosaminoglycans and proteoglycans undergo marked alterations in their content, composition and chemical structure. Int J Biochem Cell Biol 35, 376390.
  • 69
    Skandalis SS, Kletsas D, Kyriakopoulou D, Stavropoulos M & Theocharis DA (2006) The greatly increased amounts of accumulated versican and decorin with specific post-translational modifications may be closely associated with the malignant phenotype of pancreatic cancer. Biochim Biophys Acta 1760, 12171225.
  • 70
    Köninger J, Giese T, di Mola FF, Wente MN, Esposito I, Bachem MG, Giese NA, Büchler MW & Friess H (2004) Pancreatic tumor cells influence the composition of the extracellular matrix. Biochem Biophys Res Commun 322, 943949.
  • 71
    Nash MA, Loercher AE & Freedman RS (1999) In vitro growth inhibition of ovarian cancer cells by decorin: synergism of action between decorin and carboplatin. Cancer Res 59, 61926196.
  • 72
    Koninger J, Giese NA, di Mola FF, Berberat P, Giese T, Esposito I, Bachem MG, Buchler MW & Friess H (2004) Overexpressed decorin in pancreatic cancer: potential tumor growth inhibition and attenuation of chemotherapeutic action. Clin Cancer Res 10, 47764783.
  • 73
    Tralhao JG, Schaefer L, Micegova M, Evaristo C, Schonherr E, Kayal S, Veiga-Fernandes H, Danel C, Iozzo RV, Kresse H et al. (2003) In vivo selective and distant killing of cancer cells using adenovirus mediated decorin gene transfer. FASEB J 17, 464466.
  • 74
    Biglari A, Bataille D, Naumann U, Weller M, Zirger J, Castro MG & Lowenstein PR (2004) Effects of ectopic decorin in modulating intracranial glioma progression in vivo, in a rat syngeneic model. Cancer Gene Ther 11, 721732.
  • 75
    Goldoni S & Iozzo RV (2008) Tumor microenvironment: modulation by decorin and related molecules harboring leucine-rich tandem motifs. Int J Cancer 123, 24732479.
  • 76
    Goldoni S, Seidler DG, Heath J, Fassan M, Baffa R, Thakur ML, Owens RA, McQuillan DJ & Iozzo RV (2008) An anti-metastatic role for decorin in breast cancer. Am J Pathol 173, 844855.
  • 77
    Li Y, Aoki T, Mori Y, Ahmad M, Miyamori H, Takino T & Sato H (2004) Cleavage of lumican by membrane-type matrix metalloprotease-1 abrogates this proteoglycan-mediated suppression of tumor cell colony formation in soft agar. Cancer Res 64, 70587064.
  • 78
    Nikitovic D, Berdiaki A, Zafiropoulos A, Katonis P, Tsatsakis A, Karamanos N & Tzanakakis GN (2008) Lumican expression is positively correlated with the differentiation and negatively with the growth of human osteosarcoma cells. FEBS J 275, 350361.
  • 79
    Vuillermoz B, Khoruzhenko A, D’Onofrio MF, Ramont L, Venteo L, Perreau C, Antonicelli F, Maquart FX & Wegrowski Y (2004) The small leucine-rich proteoglycan lumican inhibits melanoma progression. Exp Cell Res 296, 294306.
  • 80
    Leygue E, Snell L, Dotzlaw H, Troup S, Hiller-Hitchcock T, Murphy LC, Roughley PJ & Watson PH (2000) Lumican and decorin are differentially expressed in human breast carcinoma. J Pathol 192, 313320.
  • 81
    Zeltz C, Brezillon S, Perreau C, Ramont L, Maquart F-X & Wegrowski Y (2009) Lumcorin: a leucine-rich repeat 9-derived peptide from human lumican inhibiting melanoma cell migration. FEBS Lett 583, 30273032.
  • 82
    Iozzo RV, Zoeller JJ & Nyström A (2009) Basement membrane proteoglycans: modulators par excellence of cancer growth and angiogenesis. Mol Cells 27, 503513.
  • 83
    Zhou Z, Wang J, Cao R, Morita H, Soininen R, Chan KM, Liu B, Cao Y & Tryggvason K (2004) Impaired angiogenesis, delayed wound healing and retarded tumor growth in perlecan heparan sulfate-deficient mice. Cancer Res 64, 46994702.
  • 84
    Sharma B, Handler M, Eichstetter I, Whitelock J, Nugent MA & Iozzo RV (1998) Antisense targeting of perlecan blocks tumor growth and angiogenesis in vivo. J Clin Invest 102, 15991608.
  • 85
    Kadenhe-Chiweshe A, Papa J, McCrudden KW, Frischer J, Bae J-O, Huang J, Fisher J, Lefkowitch JH, Feirt N, Rudge J et al. (2008) Sustained VEGF blockade results in microenvironmental sequestration of VEGF by tumors and persistent VEGF receptor-2 activation. Mol Cancer Res 6, 19.
  • 86
    Reiland J, Sanderson RD, Waguespack M, Barker SA, Long R, Carson DD & Marchetti D (2004) Heparanase degrades syndecan-1 and perlecan heparan sulfate: functional implications for tumor cell invasion. J Biol Chem 279, 80478055.
  • 87
    Whitelock JM, Murdoch AD, Iozzo RV & Underwood PA (1996) The degradation of human endothelial cell-derived perlecan and release of bound basic fibroblast growth factor by stromelysin, collagenase, plasmin and heparanases. J Biol Chem 271, 1007910086.
  • 88
    Bix G, Fu J, Gonzalez E, Macro L, Barker A, Campbell S, Zutter MM, Santoro SA, Kim JK, Höök M et al. (2004) Endorepellin causes endothelial cell disassembly of actin cytoskeleton and focal adhesions through the α2β1 integrin. J Cell Biol 166, 97109.
  • 89
    Nyström A, Shaik ZP, Gullberg D, Krieg T, Eckes B, Zent R, Pozzi A & Iozzo RV (2009) Role of tyrosine phosphatase SHP-1 in the mechanism of endorepellin angiostatic activity. Blood 114, 48974906.
  • 90
    Bix G, Castello R, Burrows M, Zoeller JJ, Weech M, Iozzo RA, Cardi C, Thakur MT, Barker CA, Camphausen KC et al. (2006) Endorepellin in vivo: targeting the tumor vasculature and retarding cancer growth and metabolism. J Natl Cancer Inst 98, 16341646.
  • 91
    Gonzalez EM, Reed CC, Bix G, Fu J, Zhang Y, Gopalakrishnan B, Greenspan DS & Iozzo RV (2005) BMP-1/Tolloid-like metalloproteases process endorepellin, the angiostatic C-terminal fragment of perlecan. J Biol Chem 280, 70807087.
  • 92
    Chang JW, Kang U-B, Kim DH, Yi JK, Lee JW, Noh D-Y, Lee C & Yu M-H (2008) Identification of circulating endorepellin LG3 fragment: potential use as a serological biomarker for breast cancer. Proteomics Clin Appl 2, 2332.
  • 93
    Ferreras M, Felbor U, Lenhard T, Olsen BR & Delaisse J (2000) Generation and degradation of human endostatin proteins by various proteinases. FEBS Lett 486, 247251.
  • 94
    Sund M & Kalluri R (2009) Tumor stroma derived biomarkers in cancer. Cancer Metastasis Rev 28, 177183.
  • 95
    Sauter BV, Martinet O, Zhang W-J, Mandeli J & Woo SLC (2001) Adenovirus-mediated gene transfer of endostatin in vivo results in high level of transgene expression and inhibition of tumor growth and metastasis. Proc Natl Acad Sci USA 97, 48024807.
  • 96
    Abdollahi A, Hahnfeldt P, Maercker C, Gröne H-J, Debus J, Ansorge W, Folkman J, Hlatky L & Huber PE (2004) Endostatin’s antioangiogenic signaling network. Mol Cell 13, 649663.
  • 97
    Kuo CJ, LaMontagne KR, Garcia-Cardena G, Ackley BD, Kalman D, Park S, Christofferson R, Kamihara J, Ding Y-H, Lo K-M et al. (2001) Oligomerization-dependent regulation of motility and morphogenesis by the collagen XVIII NC1/endostatin domain. J Cell Biol 152, 12331246.
  • 98
    Rodrigues DB, Chammas R, Malavasi NV, daCosta PLN, Chura-Chambi RM, Balduino KN & Morganti L (2010) Anti-tumor therapy with macroencapsulated endostatin producer cells. BMC Biotechnol 10, 19.
  • 99
    Tátrai P, Dudás J, Batmunkh E, Máthé M, Zalatnai A, Schaff Z, Ramadori G & Kovalszky I (2006) Agrin, a novel basement membrane component in human rat and liver, accumulates in cirrhosis and hepatocellular carcinoma. Lab Invest 86, 11491160.
  • 100
    Batmunkh E, Tátrai P, Szabó E, Lódi C, Holczbauer A, Páska C, Kupcsulik P, Kiss A, Schaff Z & Kovalszky I (2007) Comparison of the expression of agrin, a basement membrane heparan sulfate proteoglycan, in cholangiocarcinoma and hepatocellular carcinoma. Hum Pathol 38, 15081515.
  • 101
    Filmus J, Capurro M & Rast J (2008) Glypicans. Genome Biol 9, 224.
  • 102
    Capurro MI, Xu P, Shi W, Li F, Jia A & Filmus J (2008) Glypican-3 inhibits hedgehog signaling during development by competing with Patched for Hedgehog binding. Dev Cell 14, 700711.
  • 103
    Song HH, Shi W, Xiang Y & Filmus J (2005) The loss of glypican-3 induces alterations in Wnt signaling. J Biol Chem 280, 21162125.
  • 104
    Kirkpatrick CA, Knox SM, Staatz WD, Fox B, Lercher DM & Selleck SB (2006) The function of a Drosophila glypican does not depend entirely on heparan sulfate modification. Dev Biol 300, 570582.
  • 105
    Kleeff J, Ishiwata T, Kumbasar A, Friess H, Buchler MW, Lander AD & Korc M (1998) The cell-surface heparan sulfate proteoglycan glypican-1 regulates growth factor action in pancreatic carcinoma cells and is overexpressed in human pancreatic cancer. J Clin Invest 102, 16621673.
  • 106
    Matsuda K, Maruyama H, Guo F, Kleeff J, Itakura J, Matsumoto Y, Lander AD & Korc M (2001) Glypican-1 is overexpressed in human breast cancer and modulates the mitogenic effects of multiple heparin-binding growth factors in breast cancer cells. Cancer Res 61, 55625569.
  • 107
    Pilia G, Hughes-Benzie RM, MacKenzie A, Baybayan P, Chen EY, Huber R, Neri G, Cao A, Forabosco A & Schlessinger D (1996) Mutations in GPC3, a glypican gene, cause the Simpson–Golabi–Behmel overgrowth syndrome. Nat Genet 12, 241247.
  • 108
    Gonzalez AD, Kaya M, Shi W, Song H, Testa JR, Penn LZ & Filmus J (1998) OCI-5/GPC3, a glypican encoded by a gene that is mutated in the Simpson–Golabi–Behmel overgrowth syndrome, induces apoptosis in a cell line-specific manner. J Cell Biol 141, 14071414.
  • 109
    Kim H, Xu GL, Borczuk AC, Busch S, Filmus J, Capurro M, Brody JS, Lange J, D’Armiento JM, Rothman PB et al. (2003) The heparan sulfate proteoglycan GPC3 is a potential lung tumor suppressor. Am J Respir Cell Mol Biol 29, 694701.
  • 110
    Zhu Z, Friess H, Kleeff J, Wang L, Wirtz M, Zimmermann A, Korc M & Buchler MW (2002) Glypican-3 expression is markedly decreased in human gastric cancer but not in esophageal cancer. Am J Surg 184, 7883.
  • 111
    Lin H, Huber R, Schlessinger D & Morin PJ (1999) Frequent silencing of the GPC3 gene in ovarian cancer cell lines. Cancer Res 59, 807810.
  • 112
    Murthy SS, Shen T, De Rienzo A, Lee WC, Ferriola PC, Jhanwar SC, Mossman BT, Filmus J & Testa JR (2000) Expression of GPC3, an X-linked recessive overgrowth gene, is silenced in malignant mesothelioma. Oncogene 19, 410416.
  • 113
    Yuan Z, Goetz JA, Singh S, Ogden SK, Petty SK, Black CC, Memoli VA, Dmitrovsky E & Robbins DJ (2006) Frequent requirement of hedgehog signaling in non-small cell lung carcinoma. Oncogene 26, 10461055.
  • 114
    Kubo M, Nakamura M, Tasaki A, Yamanaka N, Nakashima H, Nomura M, Kuroki S & Katano M (2004) Hedgehog signaling pathway is a new therapeutic target for patients with breast cancer. Cancer Res 64, 60716074.
  • 115
    Saikali Z & Sinnett D (2000) Expression of glypican 3 (GPC3) in embryonal tumors. Int J Cancer 89, 418422.
  • 116
    Nakatsura T, Kageshita T, Ito S, Wakamatsu K, Monji M, Ikuta Y, Senju S, Ono T & Nishimura Y (2004) Identification of glypican-3 as a novel tumor marker for melanoma. Clin Cancer Res 10, 66126621.
  • 117
    Hippo Y, Watanabe K, Watanabe A, Midorikawa Y, Yamamoto S, Ihara S, Tokita S, Iwanari H, Ito Y, Nakano K et al. (2004) Identification of soluble NH2-terminal fragment of glypican-3 as a serological marker for early-stage hepatocellular carcinoma. Cancer Res 64, 24182423.
  • 118
    Bloushtain N, Qimron U, Bar-Ilan A, Hershkovitz O, Gazit R, Fima E, Korc M, Vlodavsky I, Bovin NV & Porgador A (2004) Membrane-associated heparan sulfate proteoglycans are involved in the recognition of cellular targets by NKp30 and NKp46. J Immunol 173, 23922401.
  • 119
    Fears CY & Woods A (2006) The role of syndecans in disease and wound healing. Matrix Biol 25, 443456.
  • 120
    Manon-Jensen T, Itoh Y & Couchman JR (2010) Proteoglycans in health and disease: the multiple roles of syndecan shedding. FEBS J 277, 38763889.
  • 121
    Chen D, Adenekan B, Chen L, Vaughan ED, Gerald W, Feng Z & Knudsen BS (2004) Syndecan-1 expression in locally invasive and metastatic prostate cancer. Urology 63, 402407.
  • 122
    Barbareschi M, Maisonneuve P, Aldovini D, Cangi MG, Pecciarini L, Mauri F, Veronese S, Caffo O, Lucenti A, Palma PD et al. (2003) High syndecan-1 expression in breast carcinoma is related to an aggressive phenotype and to poorer prognosis. Cancer 98, 474483.
  • 123
    Alexander CM, Reichsman F, Hinkes MT, Lincecum J, Becker KA, Cumberledge S & Bernfield M (2000) Syndecan-1 is required for Wnt-1-induced mammary tumorigenesis in mice. Nat Genet 25, 329332.
  • 124
    Beauvais DM & Rapraeger AC (2003) Syndecan-1-mediated cell spreading requires signaling by alphavbeta3 integrins in human breast carcinoma cells. Exp Cell Res 286, 219232.
  • 125
    Maeda T, Alexander CM & Friedl A (2004) Induction of syndecan-1 expression in stromal fibroblasts promotes proliferation of human breast cancer cells. Cancer Res 64, 612621.
  • 126
    Maeda T, Desouky J & Friedl A (2006) Syndecan-1 expression by stromal fibroblasts promotes breast carcinoma growth in vivo and stimulates tumor angiogenesis. Oncogene 2, 14081412.
  • 127
    Chang Z, Meyer K, Rapraeger AC & Friedl A (2000) Differential ability of heparan sulfate proteoglycans to assemble the fibroblast growth factor receptor complex in situ. FASEB J 14, 137144.
  • 128
    Gospodarowicz D & Cheng J (1986) Heparin protects basic and acidic FGF from inactivation. J Cell Physiol 128, 475484.
  • 129
    Anttonen A, Heikkila P, Kajant IM, Jalkanen M & Joensuu H (2001) High syndecan-1 expression is associated with favourable outcome in squamous cell lung carcinoma treated with radical surgery. Lung Cancer 32, 297305.
  • 130
    Lundin M, Nordling S, Lundin J, Wiksten J-P & Haglund C (2005) Epithelial syndecan-1 expression is associated with stage and grade in colorectal cancer. Oncology 68, 306313.
  • 131
    Shinyo Y, Kodama J, Hasengaowa, Kusumoto T & Hiramatsu Y (2005) Loss of cell-surface heparan sulfate expression in both cervical intraepithelial neoplasm and invasive cervical cancer. Gynecol Oncol 96, 776783.
  • 132
    Juuti A, Nordling S, Lundin J, Louhimo J & Haglund C (2005) Syndecan-1 expression – a novel prognostic marker in pancreatic cancer. Oncology 68, 97106.
  • 133
    Leivonen M, Lundin J, Nordling S, von Boguslawski K & Haglund C (2004) Prognostic value of syndecan-1 expression in breast cancer. Oncology 67, 1118.
  • 134
    Mukunyadzi P, Liu K, Hanna EY, Suen JY & Fan CY (2003) Induced expression of syndecan-1 in the stroma of head and neck squamous cell carcinoma. Mod Pathol 16, 796801.
  • 135
    Wiksten JP, Lundin J, Nordling S, Lundin M, Kokkola A, von Boguslawski K & Haglund C (2001) Epithelial and stromal syndecan-1 expression as predictor of outcome in patients with gastric cancer. Int J Cancer 95, 16.
  • 136
    Ding K, Lopez-Burks M, Sánchez-Duran JA, Korc M & Lander AD (2005) Growth factor-induced shedding of syndecan-1 confers glypican-1 dependence on mitogenic responses of cancer cells. J Cell Biol 171, 729738.
  • 137
    Fitzgerald ML, Wang Z, Park PW, Murphy G & Bernfield M (2000) Shedding of syndecan-1 and -4 ectodomains is regulated by multiple signaling pathways and mediated by a TIMP-3-sensitive metalloproteinase. J Cell Biol 148, 811824.
  • 138
    Wang Z, Gotte M, Bernfield M & Reizes O (2005) Constitutive and accelerated shedding of murine syndecan-1 is mediated by cleavage of its core protein at a specific juxtamembrane site. Biochemistry 44, 1235512361.
  • 139
    Yang Y, Yaccoby S, Liu W, Langford JK, Pumphrey CY, Theus A, Epstein J & Sanderson RD (2002) Soluble syndecan-1 promotes growth of myeloma tumors in vivo. Blood 100, 610617.
  • 140
    Kato M, Wang H, Kainulainen V, Fitzgerald ML, Ledbetter S, Ornitz DM & Bernfield M (1998) Physiological degradation converts the soluble syndecan-1 ectodomain from an inhibitor to a potent activator of FGF-2. Nat Med 4, 691697.
  • 141
    Marshall LJ, Ramdin LS, Brooks T, DPhil PC & Shute JK (2003) Plasminogen activator inhibitor-1 supports IL-8-mediated neutrophil transendothelialmigration by inhibition of the constitutive shedding of endothelial IL-8/heparan sulfate/syndecan-1 complexes. J Immunol 171, 20572065.
  • 142
    Munesue S, Kusano Y, Oguri K, Itano N, Yoshitomi Y, Nakanishi H, Yamashina I & Okayama M (2002) The role of syndecan-2 in regulation of actin-cytoskeletal organization of Lewis lung carcinoma-derived metastatic clones. Biochem J 363, 201209.
  • 143
    Fears CY, Gladson CL & Woods A (2006) Syndecan-2 is expressed in the microvasculature of mouse gliomas and regulates angiogenesis in microvascular endothelial cells. J Biol Chem 281, 1453314536.
  • 144
    Park H, Kim Y, Lim Y, Han I & Oh ES (2002) Syndecan-2 mediates adhesion and proliferation of colon carcinoma cells. J Biol Chem 277, 2973029736.
  • 145
    Kousidou OCh, Berdiaki A, Kletsas D, Zafiropoulos A, Theocharis AD, Tzanakakis GN & Karamanos NK (2008) Estradiol-estrogen receptor: a key interplay of the expression of syndecan-2 and metalloproteinase-9 in breast cancer cells. Mol Oncol 2, 223232.
  • 146
    Klass CM, Couchman JR & Woods A (2000) Control of extracellular matrix assembly by syndecan-2 proteoglycan. J Cell Sci 113, 493506.
  • 147
    Mundhenke C, Meyer K, Drew S & Friedl A (2002) Heparan sulfate proteoglycans as regulators of fibroblast growth factor-2 receptor binding in breast carcinomas. Am J Pathol 160, 185194.
  • 148
    Woods A, Longley RL, Tumova S & Couchman JR (2000) Syndecan-4 binding to the high affinity heparin-binding domain of fibronectin drives focal adhesion formation in fibroblasts. Arch Biochem Biophys 374, 6672.
  • 149
    Chalkiadaki G, Nikitovic D, Berdiaki A, Sifaki M, Krasagakis K, Katonis P, Karamanos NK & Tzanakakis GN (2009) Fibroblast growth factor-2 modulates melanoma adhesion and migration through a syndecan-4-dependent mechanism. Int J Biochem Cell Biol 41, 13231331.
  • 150
    Longley RL, Woods A, Fleetwood A, Cowling GJ, Gallagher JT & Couchman JR (1999) Control of morphology, cytoskeleton and migration by syndecan 4. J Cell Sci 112, 34213431.
  • 151
    Midwood KS, Mao Y, Hsia HC, Valenick LV & Schwarzbauer JE (2006) Modulation of cell–fibronectin matrix interactions during tissue repair. J Investig Dermatol Symp Proc 11, 7378.
  • 152
    Ikeda H, Hideshima T, Fulciniti M, Lutz RJ, Yasui H, Okawa Y, Kiziltepe T, Vallet S, Pozzi S, Santo L et al. (2009) The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo. Clin Cancer Res 15, 40284037.
  • 153
    Barash U, Cohen-Kapaln V, Dowek I, Sanderson RD, Ilan N & Vlodavsky I (2010) Proteoglycans in health and disease: new concpts for heparanase function in tumor progression and metastasis. FEBS J 277, 38903903.
  • 154
    Fux L, Ilan N, Sanderson RD & Vlodavsky I (2009) Heparanase: busy at the cell surface. Trends Biochem Sci 34, 511519.
  • 155
    Kolset SO & Tveit H (2008) Serglycin – structure and biology. Cell Mol Life Sci 65, 10731085.
  • 156
    Niemann CU, Kjeldsen L, Ralfkiaer E, Jensen MK & Borregaard N (2007) Serglycin proteoglycan in hematologic malignancies: a marker of acute myeloid leukemia. Leukemia 21, 24062410.
  • 157
    Theocharis AD, Seidel C, Borset M, Dobra K, Baykov V, Labropoulou V, Kanakis I, Dalas E, Karamanos NK, Sundan A et al. (2006) Serglycin constitutively secreted by myeloma plasma cells is a potent inhibitor of bone mineralization in vitro. J Biol Chem 281, 3511635128.